Saturday, February 24, 2018

Two New Studies Demonstrate T2Candida’s Advantages over Current Diagnostic Testing

Tailwinds' Take: further confirmation of the effectiveness of T2's system. We are highly confident in near-term approval. Even better, many predict slow uptake; we...

T2 Biosystems: Looking to Disarm the “Silent Killer” Known As Sepsis

Sepsis is a state of an infectious disease, starting when a bacteria or fungus enters a person’s bloodstream, that can lead to tissue damage,...

T2 Biosystems (TTOO) Added to the Tailwinds Select Portfolio

We have added T2 Biosystems to the Select Portfolio. T2 is well positioned to receive FDA approval on their sepsis diagnostic sometime in Q1....

T2 Biosystems Announces Preliminary Fourth Quarter 2017 Financial Results and Provides Update on T2Bacteria...

LEXINGTON, Mass., Jan. 04, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development of innovative medical diagnostic products for critical unmet needs in healthcare, today...

T2 Biosystems Announces New T2Bacteria RUO Panel Data Presented at AMP 2017

LEXINGTON, Mass., Nov. 20, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare, today...
Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address